Your browser doesn't support javascript.
Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers.
Joy, George; Artico, Jessica; Kurdi, Hibba; Seraphim, Andreas; Lau, Clement; Thornton, George D; Oliveira, Marta Fontes; Adam, Robert Daniel; Aziminia, Nikoo; Menacho, Katia; Chacko, Liza; Brown, James T; Patel, Rishi K; Shiwani, Hunain; Bhuva, Anish; Augusto, Joao B; Andiapen, Mervyn; McKnight, Aine; Noursadeghi, Mahdad; Pierce, Iain; Evain, Timothée; Captur, Gabriella; Davies, Rhodri H; Greenwood, John P; Fontana, Marianna; Kellman, Peter; Schelbert, Erik B; Treibel, Thomas A; Manisty, Charlotte; Moon, James C.
  • Joy G; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Artico J; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Kurdi H; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Seraphim A; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Lau C; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
  • Thornton GD; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Oliveira MF; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Cardiology Department, University Hospital Centre of Porto, Porto, Portugal.
  • Adam RD; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Aziminia N; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom.
  • Menacho K; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Chacko L; Institute of Cardiovascular Science, University College London, London, United Kingdom; National Amyloidosis Centre, Division of Medicine, University College London, London, United Kingdom; Royal Free London NHS Foundation Trust, Pond Street, London, United Kingdom.
  • Brown JT; Institute of Cardiovascular Science, University College London, London, United Kingdom; National Amyloidosis Centre, Division of Medicine, University College London, London, United Kingdom; Royal Free London NHS Foundation Trust, Pond Street, London, United Kingdom.
  • Patel RK; Institute of Cardiovascular Science, University College London, London, United Kingdom; National Amyloidosis Centre, Division of Medicine, University College London, London, United Kingdom; Royal Free London NHS Foundation Trust, Pond Street, London, United Kingdom.
  • Shiwani H; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Bhuva A; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Augusto JB; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom; Cardiology Department, Hospital Prof Doutor Fernando Fonseca Amadora, Portugal.
  • Andiapen M; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
  • McKnight A; Blizard Institute, Queen Mary University of London, London, United Kingdom.
  • Noursadeghi M; Division of Infection and Immunity, University College London, London, United Kingdom.
  • Pierce I; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Evain T; Imageens, Paris, France.
  • Captur G; Institute of Cardiovascular Science, University College London, London, United Kingdom; Royal Free London NHS Foundation Trust, Pond Street, London, United Kingdom.
  • Davies RH; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Greenwood JP; Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
  • Fontana M; Institute of Cardiovascular Science, University College London, London, United Kingdom; National Amyloidosis Centre, Division of Medicine, University College London, London, United Kingdom; Royal Free London NHS Foundation Trust, Pond Street, London, United Kingdom.
  • Kellman P; National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, Maryland, USA.
  • Schelbert EB; UPMC CMR Center, UPMC, Pittsburgh, Pennsylvania, USA.
  • Treibel TA; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Manisty C; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Moon JC; Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom. Electronic address: j.moon@ucl.ac.uk.
JACC Cardiovasc Imaging ; 14(11): 2155-2166, 2021 11.
Article in English | MEDLINE | ID: covidwho-1225278
ABSTRACT

OBJECTIVES:

The purpose of this study was to detect cardiovascular changes after mild severe acute respiratory syndrome-coronavirus-2 infection.

BACKGROUND:

Concern exists that mild coronavirus disease 2019 may cause myocardial and vascular disease.

METHODS:

Participants were recruited from COVIDsortium, a 3-hospital prospective study of 731 health care workers who underwent first-wave weekly symptom, polymerase chain reaction, and serology assessment over 4 months, with seroconversion in 21.5% (n = 157). At 6 months post-infection, 74 seropositive and 75 age-, sex-, and ethnicity-matched seronegative control subjects were recruited for cardiovascular phenotyping (comprehensive phantom-calibrated cardiovascular magnetic resonance and blood biomarkers). Analysis was blinded, using objective artificial intelligence analytics where available.

RESULTS:

A total of 149 subjects (mean age 37 years, range 18 to 63 years, 58% women) were recruited. Seropositive infections had been mild with case definition, noncase definition, and asymptomatic disease in 45 (61%), 18 (24%), and 11 (15%), respectively, with 1 person hospitalized (for 2 days). Between seropositive and seronegative groups, there were no differences in cardiac structure (left ventricular volumes, mass, atrial area), function (ejection fraction, global longitudinal shortening, aortic distensibility), tissue characterization (T1, T2, extracellular volume fraction mapping, late gadolinium enhancement) or biomarkers (troponin, N-terminal pro-B-type natriuretic peptide). With abnormal defined by the 75 seronegatives (2 SDs from mean, e.g., ejection fraction <54%, septal T1 >1,072 ms, septal T2 >52.4 ms), individuals had abnormalities including reduced ejection fraction (n = 2, minimum 50%), T1 elevation (n = 6), T2 elevation (n = 9), late gadolinium enhancement (n = 13, median 1%, max 5% of myocardium), biomarker elevation (borderline troponin elevation in 4; all N-terminal pro-B-type natriuretic peptide normal). These were distributed equally between seropositive and seronegative individuals.

CONCLUSIONS:

Cardiovascular abnormalities are no more common in seropositive versus seronegative otherwise healthy, workforce representative individuals 6 months post-mild severe acute respiratory syndrome-coronavirus-2 infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Abnormalities / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adolescent / Adult / Female / Humans / Male / Middle aged / Young adult Language: English Journal: JACC Cardiovasc Imaging Journal subject: Vascular Diseases / Cardiology / Diagnostic Imaging Year: 2021 Document Type: Article Affiliation country: J.jcmg.2021.04.011

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Abnormalities / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adolescent / Adult / Female / Humans / Male / Middle aged / Young adult Language: English Journal: JACC Cardiovasc Imaging Journal subject: Vascular Diseases / Cardiology / Diagnostic Imaging Year: 2021 Document Type: Article Affiliation country: J.jcmg.2021.04.011